Key result
KCNJ11 CC genotype, triglycerides <1.7, and DBP <90 are linked to ~100% greater DPP-4i response.
Why the study?
Do specific clinical and genetic factors predict HbA1c response to DPP-4 inhibitors in patients with Type 2 diabetes mellitus?
Cohort (n=662)
Do specific clinical and genetic factors predict HbA1c response to DPP-4 inhibitors in patients with Type 2 diabetes mellitus?
Lower triglycerides, lower diastolic blood pressure, and the KCNJ11 rs2285676 CC genotype are significant predictors of favorable HbA1c response to DPP-4 inhibitors in patients with Type 2 diabetes.
These associations should not yet guide DPP-4 inhibitor use; hypothesis-generating and requires prospective validation.
AIM: To determine the clinical and genetic predictors of the dipeptidyl peptidase-4 (DPP-4) inhibitor treatment response in Type 2 diabetes mellitus (T2DM) patients. PATIENTS & METHODS: DPP4, WFS1 and KCNJ11 gene polymorphisms were genotyped in a cohort study of 662 T2DM patients treated with DPP-4 inhibitors sitagliptin, vildagliptin or linagliptin. Genotyping was performed by Applied Biosystems TaqMan SNP genotyping assay. RESULTS: Patients with triglyceride levels less than 1.7 mmol/l (odds ratio [OR]: 2.2.; 95% CI: 1.031-4.723), diastolic blood pressure (DBP) less than 90 mmHg (OR: 1.7; 95% CI: 1.009-2.892) and KCNJ11 rs2285676 (genotype CC) (OR: 2.0; 95% CI: 1.025-3.767) were more likely to response to DPP-4 inhibitor treatment compared with other patients, as measured by HbA1c levels. CONCLUSION: Triglycerides, DBP and KCNJ11 rs2285676 are predictors of the DPP-4 inhibitor treatment response in T2DM patients.
No takes yet. Share an insight, caveat, or question.
Jamaluddin et al. (2016) conducted a cohort in Type 2 diabetes mellitus (n=662). KCNJ11 rs2285676 (genotype CC), triglycerides <1.7 mmol/l, and DBP <90 mmHg vs. Other patients was evaluated on Response to DPP-4 inhibitor treatment as measured by HbA1c levels (OR 2.0, 95% CI 1.025-3.767). KCNJ11 rs2285676 genotype CC, triglycerides <1.7 mmol/l, and DBP <90 mmHg were associated with a higher likelihood of response to DPP-4 inhibitors (OR 2.0; 95% CI 1.025-3.767 for KCNJ11).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: